On the 14 March 2024 Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, announced a €30 million Series A financing. The funds will be used to support development of Asgard´s lead program AT-108 to IND-readiness by 2026, expand and reinforce its research and development team, and fuel new reprogramming modalities and delivery platforms to strengthen the pipeline. The round was co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc., with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.
“Asgard’s technology overcomes challenges faced by traditional cell therapies, enabling the recreation of desired functional immune cells directly inside the patient’s body. We believe this breakthrough strategy will give rise to the next generation of cell therapies. This financing also follows a strong pre-clinical package providing PoC for AT-108. We would like to thank both new and existing investors for their support as we discover and develop innovative immunotherapies with breakthrough potential and look forward to progressing our lead program AT-108 to the clinic.” says Cristiana Pires, Co-founder and Chief Executive Officer of Asgard Therapeutics
“We’re thrilled to welcome new investors JJDC and RV Invest to Asgard Therapeutics. This marks a significant milestone for Asgard’s novel concept of direct in vivo cellular reprogramming in oncology. We’re proud to continue to support Asgard in its mission to bring an off-the-shelf personalized therapy to the clinic and deliver on the promise of the technology for the benefit of patients.” says João Ribas, Principal, Novo Holdings, Seed Investments.
Medicon Valley Alliance would like to congratulate Cristiana and her team AND SmiLe Incubator with this excellent news, which testifies to the importance of strengthening Danish-Swedish life science.
Read full press release